CN104881579A - Method for screening traditional Chinese medicine composition for treating qi stagnation type epigastric pain - Google Patents
Method for screening traditional Chinese medicine composition for treating qi stagnation type epigastric pain Download PDFInfo
- Publication number
- CN104881579A CN104881579A CN201510269325.4A CN201510269325A CN104881579A CN 104881579 A CN104881579 A CN 104881579A CN 201510269325 A CN201510269325 A CN 201510269325A CN 104881579 A CN104881579 A CN 104881579A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- epigastric pain
- stagnation type
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided is a method for screening a traditional Chinese medicine composition for treating qi stagnation type epigastric pain. An 'effective prescription hypothesis' is provided under the guidance of the traditional Chinese medicine theory, a modern pharmacology method is applied, a 'pharmacological model screening system' is designed for gastric acid, stomachaches, gasteremphraxis and other qi stagnation type epigastric pain diseases, and the new traditional Chinese medicine composition is screened through a contribution degree evaluation method of the 'composition contribution degree' and the 'comprehensive contribution degree'. Compared with a traditional Chinese medicine compatibility method, and the component and proportional relation of the new composition reflects the independent and synergetic contribution capacity of all the components in treating the qi stagnation type epigastric pain diseases more clearly. The screening method is simple and practicable in procedure, a new method is provided for finding and research of the new traditional Chinese medicine composition of the qi stagnation type epigastric pain and compatibility theoretical research of a traditional prescription, and a new screening idea is provided for developing the medicine composition of other diseases.
Description
Technical field
The invention belongs to biology and medical art, be specifically related to a kind of screening technique for the treatment of Qi-stagnation type epigastric pain Chinese medicine composition, belong to biological and medical art.
background technology:
In Chinese medicinal formulae, complicacy, the multiple spot of effect, the comprehensive coordination property of composition, consistent with the complicacy feature of organism disease, embodies tcm treatment according to syndrome differentiation feature.Because Chinese Traditional Medicine compatibility is mainly based on summary of experience, lack the checking of modern scientific method.Therefore, set up the prescription screening method for organism disease complication system, science illustrates independent action and the combined action of each component in prescription, carries out tcm components research on this basis, is the main task of drug matching research.
Current most of study of tcm new drug thinking still with classic prescriptions, clinical experience prescription for foundation, by pharmacodynamic study, clinical experimental study etc. exploitation new Chinese medicine.
Along with the scientific technological advance of advanced person, bioactive components research, study on mechanism, compatibility research, inside and outside pharmaceutical research, clinical experimental study etc. are extensively carried out, for the modernization of Chinese medicine and standardization have played important facilitation.At present, prepared slices of Chinese crude drugs list is decocted and is mixed decoction comparative studies, the side of tearing open and plus-minus optimizing research, network pharmacology theoretical origin, bioavailability study method, serum pharmaceutical chemistry research method, molecule knocks out the application of technology, and nanometer technology improves bioavailability study etc. report more.But the research of Chinese medicinal formulae compatibility not yet forms a set of simple and effective screening technique.
summary of the invention:
The object of this invention is to provide one and treat Qi-stagnation type epigastric pain Chinese medicine composition screening technique, selected for prescription, improve the science of compatibility, overcome the deficiency that the precision of prescription screening is in the past not high
Screening technique of the present invention comprises:
1, follow traditional Chinese medicine theory and propose effective prescription hypothesis, and determine each active principle in prescription.Using modern pharmacology method, for Qi-stagnation type epigastric pain disease design pharmacology model discrimination systems such as hydrochloric acid in gastric juice, stomachache, gasteremphraxis, by evaluating the contribution degree of each component in pharmacological model screening system, screening new Chinese medicine composition.
2. Chinese medicine composition screening technique has following steps:
2.1., effective prescription hypothesis is proposed: according to traditional Chinese medical theory, by to traditional classical prescription screening, or by literature search and statistical study, or research etc. by experiment, design can treat the prescription of Qi-stagnation type epigastric pain disease, proposes " effective prescription hypothesis ".
2.2. determine active principle: by known active component and experimental studies results, define the active principle for treatment Qi-stagnation type epigastric pain disease in efficacious prescriptions agent.
2.3. active principle is prepared: obtain clear and definite, the quality controllable component of content through extraction, purifying.
2.4. set up pharmacological model screening system: according to Qi-stagnation type epigastric pain disease disease, for the relevant pharmacological model of the designs such as hydrochloric acid in gastric juice, stomachache, gasteremphraxis, form pharmacological model screening system.
2.5. by the test findings of active principle in pharmacological model screening system, pharmacological test data is obtained;
2.6. according to " contribution degree evaluation method ", the contribution degree of active principle in pharmacological model screening system is evaluated;
2.7. according to component each in contribution degree evaluation result " comprehensive contribution degree ", optimize and produce component formation clearly, component ratio is clear and definite, the Chinese medicine composition that drug effect is clear and definite;
2.8. carry out verifying for the system pharmacodynamics of Qi-stagnation type epigastric pain to the Chinese medicine composition optimized.
3. contribution degree evaluation method comprises " component contributions degree " and " comprehensive contribution degree ", and concrete calculating and evaluation method are:
3.1. " component contributions degree ": refer to and the ability that this component is contributed for test model effect represent with S.
Wherein:
X: administration group index result; M: model group index result.
3.2. " comprehensive contribution degree ": the integration capability contributed when referring to and represent that this component acts on pharmacological model screening system, ∑ is used
srepresent.
3.3. contribution degree evaluation:
" component contributions degree " clearly each component action direction and target spot is compared for single model.Example S
a>S
b, represent that component A ability is higher than B component when acting on this model;
Compare " comprehensive contribution degree " for disease disease, specify each component to disease ability to function, routine ∑ S
a> ∑ S
b, represent and act on this disease disease component A ability higher than B component.And the Chinese medicine composition for the treatment of Qi-stagnation type epigastric pain is filtered out according to the ratio between " comprehensive contribution degree ".
" effective prescription hypothesis " wherein, according to traditional Chinese medical theory, by traditional classical prescription screening, or by literature search and statistical study, the prescription of design treatment Qi-stagnation type epigastric pain, proposes " effective prescription hypothesis ".
Described " active principle " is taken from technological standards that each single medicinal material in " effective prescription hypothesis " obtains through extracting and developing, purifying, concentrated, drying and other steps and the clear and definite extract of quality standard, its Fingerprints is clear and definite, effective constituent or effective component group content's index clear and definite.
Described " pharmacological model screening system ", is made up of pharmacological test procedures such as the animal test models such as gastric emptying, small intestine push, analgesia, anti-inflammatory and smooth muscle spasmolysis experiment in vitro, as the screening system of the new Chinese medicine composition of Qi-stagnation type epigastric pain.
Described " new Chinese medicine composition ", obtains according to the described screening step of screening technique the 2nd, be used for the treatment of Qi-stagnation type epigastric pain disease by clearly forming and the Chinese medicine composition of ratio.
The present invention's good effect of the present invention is: to treat for the purpose of the new composition screening study of Qi-stagnation type epigastric pain, establish a kind of new pharmaceutical composition screening technique being evaluated as core with " contribution degree ", not only obtain new effective composition, also for the new pharmaceutical composition screening of other class diseases provides one can the method for reference.The composition screening acquisition is in this way: bupleurum total saponin 5 weight portion: root of herbaceous peony total saposins 3 weight portion: Fructus Aurantii volatile oil 4 weight portion: Rhizoma Cyperi volatile oil 4 weight portion: Corydalis ambigua total alkaloid 2 weight portion: glycyrrhiza total flavonoid 3 weight portion.
Claims (7)
1. a treatment Qi-stagnation type epigastric pain Chinese medicine composition screening technique, it is characterized in that: follow traditional Chinese medicine theory and propose effective prescription hypothesis, and determine each active principle in prescription, use modern pharmacology method, for Qi-stagnation type epigastric pain disease design pharmacology model discrimination systems such as hydrochloric acid in gastric juice, stomachache, gasteremphraxis, by evaluating the contribution degree of each component in pharmacological model screening system, screen new Chinese medicine composition.
2. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: have following steps:
(1) effective prescription hypothesis is proposed;
(2) active principle is determined;
(3) active principle is prepared;
(4) pharmacological model screening system is set up;
(5) in the test of pharmacological model screening system, pharmacological test data is obtained by active principle;
(6) contribution degree of active principle in pharmacological model screening system is evaluated;
(7) composition is obtained according to the screening of contribution degree evaluation result;
(8) composition pharmacodynamics checking, obtains new Chinese medicine composition.
3. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: " contribution degree " wherein comprises " component contributions degree " and " comprehensive contribution degree ", and calculates by the following method:
" component contributions degree ": refer to and the ability that this component is contributed for test model effect represent with S,
Wherein:
X: administration group index result; M: model group index result
" comprehensive contribution degree ": the integration capability contributed when referring to that this component acts on pharmacological model screening system, uses ∑
srepresent.
4. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: " effective prescription hypothesis " is wherein according to traditional Chinese medical theory, by to traditional classical prescription screening, or by literature search and statistical study, the prescription of design treatment Qi-stagnation type epigastric pain, proposes " effective prescription hypothesis ".
5. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: described " active principle " gets technological standards that each single medicinal material in " the effective prescription hypothesis " in claim 4 obtains through extracting and developing, purifying, concentrated, drying and other steps and the clear and definite extract of quality standard, its Fingerprints is clear and definite, effective constituent or effective component group content's index clear and definite.
6. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: described " pharmacological model screening system ", be made up of pharmacological test procedures such as the animal test models such as gastric emptying, small intestine push, analgesia, anti-inflammatory and smooth muscle spasmolysis experiment in vitro, as the screening system of the new Chinese medicine composition of Qi-stagnation type epigastric pain.
7. one treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique according to claim 1, it is characterized in that: described " new Chinese medicine composition ", obtain according to screening technique described in claim 2, be used for the treatment of Qi-stagnation type epigastric pain disease by clearly forming and the Chinese medicine composition of ratio.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510269325.4A CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510269325.4A CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104881579A true CN104881579A (en) | 2015-09-02 |
| CN104881579B CN104881579B (en) | 2018-02-16 |
Family
ID=53949072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510269325.4A Active CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104881579B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105758950A (en) * | 2016-02-26 | 2016-07-13 | 辽宁中医药大学 | Quality control method based on dose-effect color card for anti-inflammatory and analgesia action of qi-stagnation and stomachache granules |
| CN105758949A (en) * | 2016-02-26 | 2016-07-13 | 辽宁中医药大学 | Quality control method of gastrointestinal motility promoting power of qi-stagnation and stomachache granules based on dose-effect color card |
| CN105920112A (en) * | 2016-06-07 | 2016-09-07 | 浙江省中医院 | Traditional Chinese medicine composition and application thereof |
| CN112667922A (en) * | 2021-01-12 | 2021-04-16 | 山东大学 | Novel coronavirus traditional Chinese medicine formula recommendation method and system based on collaborative filtering |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473583A (en) * | 2002-08-05 | 2004-02-11 | 浙江大学 | Researching and preparing method for new Chinese medicine |
| CN1899315A (en) * | 2005-07-22 | 2007-01-24 | 清华大学 | Developing method for Chinese medicine compound secondary new medicine |
| CN101190240A (en) * | 2006-11-22 | 2008-06-04 | 张贵君 | Component traditional Chinese medicine research approach and technology path |
| CN102445513A (en) * | 2011-09-22 | 2012-05-09 | 成龙 | A (Absorption)-M (Metabolization)-model-based traditional Chinese medicine new drug discovery policy and medicine and combination thereof |
| CN102652791A (en) * | 2011-07-25 | 2012-09-05 | 长春康彼达科技有限公司 | Medicinal composition with hepatic fibrosis resistance and preparation method |
| WO2013067322A1 (en) * | 2011-11-03 | 2013-05-10 | Stc Biologics, Inc. | Method for determination of pharmacological properties of recombinant proteins |
-
2015
- 2015-05-25 CN CN201510269325.4A patent/CN104881579B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473583A (en) * | 2002-08-05 | 2004-02-11 | 浙江大学 | Researching and preparing method for new Chinese medicine |
| CN1899315A (en) * | 2005-07-22 | 2007-01-24 | 清华大学 | Developing method for Chinese medicine compound secondary new medicine |
| CN101190240A (en) * | 2006-11-22 | 2008-06-04 | 张贵君 | Component traditional Chinese medicine research approach and technology path |
| CN102652791A (en) * | 2011-07-25 | 2012-09-05 | 长春康彼达科技有限公司 | Medicinal composition with hepatic fibrosis resistance and preparation method |
| CN102445513A (en) * | 2011-09-22 | 2012-05-09 | 成龙 | A (Absorption)-M (Metabolization)-model-based traditional Chinese medicine new drug discovery policy and medicine and combination thereof |
| WO2013067322A1 (en) * | 2011-11-03 | 2013-05-10 | Stc Biologics, Inc. | Method for determination of pharmacological properties of recombinant proteins |
Non-Patent Citations (1)
| Title |
|---|
| 王为群: "胃脘痛有效方药的筛选与评价", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105758950A (en) * | 2016-02-26 | 2016-07-13 | 辽宁中医药大学 | Quality control method based on dose-effect color card for anti-inflammatory and analgesia action of qi-stagnation and stomachache granules |
| CN105758949A (en) * | 2016-02-26 | 2016-07-13 | 辽宁中医药大学 | Quality control method of gastrointestinal motility promoting power of qi-stagnation and stomachache granules based on dose-effect color card |
| CN105758950B (en) * | 2016-02-26 | 2018-02-06 | 辽宁中医药大学 | Qizhi weitong granules anti-inflammatory and antalgic method of quality control based on dose-effect colour atla |
| CN105758949B (en) * | 2016-02-26 | 2018-02-06 | 辽宁中医药大学 | Qizhi weitong granules based on dose-effect colour atla promotees gastroenteritic power method of quality control |
| CN105920112A (en) * | 2016-06-07 | 2016-09-07 | 浙江省中医院 | Traditional Chinese medicine composition and application thereof |
| CN105920112B (en) * | 2016-06-07 | 2019-11-26 | 浙江省中医院 | A kind of Chinese medicine composition and its application |
| CN112667922A (en) * | 2021-01-12 | 2021-04-16 | 山东大学 | Novel coronavirus traditional Chinese medicine formula recommendation method and system based on collaborative filtering |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104881579B (en) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis | |
| Patil et al. | Anti‐arthritic activity of bartogenic acid isolated from fruits of Barringtonia racemosa Roxb.(Lecythidaceae) | |
| Lee et al. | Panax ginseng pharmacopuncture: current status of the research and future challenges | |
| CN104881579A (en) | Method for screening traditional Chinese medicine composition for treating qi stagnation type epigastric pain | |
| Chen et al. | Study on the potential active components and molecular mechanism of Xiao Huoluo Pills in the treatment of cartilage degeneration of knee osteoarthritis based on bioinformatics analysis and molecular docking technology | |
| Wu et al. | Optimization of combinations of ginsenoside-Rg 1, ginsenoside-Rb 1, evodiamine and rutaecarpine for effective therapy of mouse migraine | |
| Huang et al. | Ethanolic extracts of adlay testa and hull and their active biomolecules exert relaxing effect on uterine muscle contraction through blocking extracellular calcium influx in ex vivo and in vivo studies | |
| Yang et al. | Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer | |
| Kim et al. | Simultaneous determination of the traditional herbal formula Ukgansan and the in vitro antioxidant activity of ferulic acid as an active compound | |
| CN112107662B (en) | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof | |
| CN110751981A (en) | Analysis method for explaining essence of traditional Chinese medicine syndrome based on system biology | |
| Mao et al. | San Pian decoction can treat nitroglycerin-induced migraine in rats by inhibiting the PI3K/AKT and MAPK signaling pathways | |
| Xia et al. | Study on the Spectrum‐Effect Relationship of the Traditional Effect of Saponins in Glycyrrhiza uralensis Fisch | |
| Ali et al. | Role of unani medicines in cancer control and management | |
| CN104056281B (en) | A kind of method and application thereof for screening active constituent from Chinese medicine or natural drug complex system | |
| CN108078965A (en) | A kind of drug for being used for drug rehabilitation and preparation method thereof | |
| Yu et al. | Analysis of herbal mechanisms and prescriptions for chronic cerebral circulatory insufficiency based on data mining and network pharmacology | |
| Gamde et al. | Histopathological and biochemical effects of aqueous leaf extract of Cadaba farinosa on the liver of adult wistar rats | |
| Qiu et al. | Study on the Spectrum‐Effect Correlation of Anti‐Inflammatory Active Extract of Sauropus spatulifolius Beille | |
| Pon et al. | Harnessing traditional Chinese medicine to improve cancer therapy: issues for future development | |
| CN102240332A (en) | Pharmaceutical composition and application thereof | |
| CN103301414B (en) | Gout, short kidney are arranged, repair kidney damages pharmaceutical composition and its preparation method and application | |
| CN104435231A (en) | Method for preparing medicine preparation named Fangfengtongsheng | |
| CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| Yuan et al. | Study on the mechanism of Erzhi Pill in the treatment of breast cancer based on network pharmacology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Lu Inventor after: Su Ting Inventor before: Gao Lu |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190121 Address after: Room 607, Amendment Building, 1369 Shunda Road, Changchun High-tech Zone, Jilin Province, 130012 Patentee after: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. Address before: 130103 No. 1369 Shunda Road, Changchun High-tech Zone, Jilin Province Patentee before: Changchun Kangbida Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |